Baker McKenzie advised Xbrane on the deal.
Xbrane Biopharma AB (publ) completed a private placement of shares through an accelerated book building procedure, providing the company with proceeds of approximately SEK 146 million (approx. €13.8 million) before costs related to the transaction.
Xbrane Biopharma AB is a biopharmaceutical company. The Company specializes in the production of complex generics. Xbrane Biopharma serves customers globally.
Vator Securities AB acted as Global Coordinator and Sole Bookrunner to Xbrane.
The Baker McKenzie team was led by Joakim Falkner (Picture), Ian Gulam and Olof Larsson.
Law Firms: Baker McKenzie;
Clients: Xbrane Biopharma;